Disease Landscape and Forecast Insights

The prevalence of spondyloarthritis is increasing in China, where the estimated number of total prevalent cases of ankylosing spondylitis (AS) exceeds 1.6 million. Although the total prevalence of…

Introduction Rheumatoid arthritis (RA) affects a significant percentage of Argentinian and Mexican populations and often requires the use of premium-priced biologics. Rheumatologists have…

Introduction:The prevalence of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in Brazil and Mexico is estimated at 1.3 million and is expected to keep growing. The entry of biosimilars…

Introduction Rheumatoid arthritis (RA) is a chronic disease that affects more than 1 million Brazilians and often requires the use of premium-priced therapies. The coverage of these drugs is…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…

Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…

Type 2 diabetes and obesity are chronic diseases that affect millions of Americans and represent a costly expense for the nation’s healthcare payers. In the effort to manage quality and costs…

Neuropathic pain (NP) is a prominent form of pain associated with a variety of diseases and conditions, including cancer, diabetes, herpes zoster, chronic back pain, and multiple sclerosis. A…

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and axial skeleton, causing pain and greatly impacting quality of life. Diagnosis can be difficult,…

The past two decades have seen the arrival of revolutionary new biologic therapies for the treatment of numerous diseases, including inflammatory, hematologic, and malignant conditions. The…

Over the last 15 years, we have witnessed a notable shift in oncology drug development activity. Since the U.S. approval of Roche/Genentech’s Herceptin (trastuzumab) in 1998, pharmaceutical…